<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>SECURITIES AND EXCHANGE COMMISSION &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TITLE>
<META NAME="author" CONTENT="Administrator">
<META NAME="date" CONTENT="03/29/2007">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:468pt"><P style="line-height:16pt; margin:0pt; padding-top:3pt; font-size:14pt; border-top:3pt solid #000000" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0pt" align=center><B>Washington, D.C. &nbsp;20549</B></P>
<P style="margin:0pt"><BR></P>
<P style="line-height:16pt; margin:0pt; font-size:14pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt" align=center>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</P>
<P style="margin:0pt" align=right><BR></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center><B><U>April 3, 2007</U></B></P>
<P style="line-height:10pt; margin:0pt; font-size:8pt" align=center>Date of Report (Date of earliest event reported)</P>
<P style="margin:0pt"><BR></P>
<P style="line-height:20pt; margin:0pt; font-size:18pt" align=center><B><U>PHYTOMEDICAL TECHNOLOGIES, INC.</U></B></P>
<P style="line-height:10pt; margin:0pt; font-size:8pt" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0pt" align=center><BR></P>
<P style="margin:0pt" align=center><B><U>NEVADA</U></B></P>
<P style="line-height:10pt; margin:0pt; font-size:8pt" align=center>(State or other jurisdiction of incorporation)</P>
<P style="margin:0pt" align=center><BR></P>
<P style="margin:0pt" align=center><B><U>000-28790</U></B></P>
<P style="line-height:10pt; margin:0pt; font-size:8pt" align=center>(Commission File Number)</P>
<P style="margin:0pt" align=center><BR></P>
<P style="margin:0pt" align=center><B><U>87-0429962</U></B></P>
<P style="line-height:10pt; margin:0pt; font-size:8pt" align=center>(I.R.S. Employer Identification No.)</P>
<P style="margin:0pt" align=center><BR></P>
<P style="margin:0pt" align=center><B><U>100 Overlook Drive, 2nd Floor, Princeton, NJ &nbsp;08540</U></B></P>
<P style="line-height:10pt; margin:0pt; font-size:8pt" align=center>(Address of principal executive offices)</P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt" align=center><B><U>(800) 611-3388</U></B></P>
<P style="line-height:10pt; margin:0pt; font-size:8pt" align=center>(Registrant&#146;s telephone number, including area code)</P>
<P style="margin:0pt" align=center><BR></P>
<P style="margin:0pt; font-family:TimesNewRoman"><FONT FACE="TimesNewRoman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</FONT></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt; font-family:TimesNewRoman">[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
<P style="margin:0pt; font-family:TimesNewRoman">[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
<P style="margin:0pt; font-family:TimesNewRoman">[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style="margin:0pt; font-family:TimesNewRoman">[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style="margin:0pt; padding-bottom:3pt; border-bottom:3pt solid #000000" align=center><BR></P>
<P style="margin:0pt" align=center><BR></P>
<P style="margin:0pt"><FONT FACE="Times New Roman"><B>SECTION 1. Registrant's Business and Operations</B></FONT></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><U>Item 1.01 Entry into a Material Definitive Agreement</U></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt" align=justify>PhytoMedical Technologies, Inc., through its wholly owned subsidiary, PolyPhenol Technologies Corporation has entered into an expanded sponsored research agreement with Iowa State University (ISU) to develop, market and distribute novel synthesized compounds derived from type A-1 polyphenols. &nbsp;This sponsored research agreement between the Iowa State University and PolyPhenol Technologies Corporation is attached as Exhibit 10.1.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt"><B>SECTION 2. &nbsp;Financial Information</B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt" align=justify>None.</P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><B>SECTION 3. &nbsp;Securities and Trading Markets</B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt" align=justify>None.</P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><B>SECTION 4. &nbsp;Matters Related to Accountants and Financial Statements</B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt">None.</P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
<HR style="margin-top:7.2pt; margin-bottom:7.2pt" noshade size=1.333>
<P style="margin:0pt; page-break-before:always"><B>SECTION 5. &nbsp;Corporate Governance and Management</B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt" align=justify>None.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify><B>SECTION 6. [Reserved]</B></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify>N/A.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify><B>SECTION 7. &nbsp;Regulation FD</B></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify>None.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify><B>SECTION 8. &nbsp;Other Events</B></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify>None.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify><B>SECTION 9. &nbsp;Financial Statements and Exhibits</B></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify><U>Item 9.01 &nbsp;Financial Statements and Exhibits</U></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify>The following exhibits are furnished as part of this report:</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify>Exhibit 10.1 &#150; Sponsored Research Agreement between PolyPhenol Technologies Corporation and Iowa State University</P>
<P style="margin:0pt" align=center><BR></P>
<P style="margin:0pt" align=center><BR></P>
<P style="margin:0pt" align=center><BR></P>
<P style="margin:0pt" align=center><B>SIGNATURES</B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt" align=justify>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin-top:0pt; margin-bottom:-12pt; text-indent:33.5pt"><B>&nbsp;</B></P>
<P style="margin:0pt; text-indent:216pt"><B>PHYTOMEDICAL TECHNOLOGIES, INC.</B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt; padding-left:216pt"><U>/s/ Greg Wujek</U></P>
<P style="margin:0pt; text-indent:216pt">Greg Wujek</P>
<P style="margin:0pt; text-indent:216pt">President and CEO</P>
<P style="margin:0pt; padding-left:288pt; text-indent:-72pt" align=justify>&nbsp;</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify>Date: April 5, 2007</P>
<P style="margin:0pt" align=justify><BR>
<BR></P>
</DIV></BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "pytoapril52007isuandpr.htm", "secsgml_size_bytes": 7960}]
{"company-data": {"conformed-name": "PHYTOMEDICAL TECHNOLOGIES INC", "cik": "0001002422", "assigned-sic": "8093", "irs-number": "870429962", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28790", "film-number": "07751250"}, "business-address": {"street1": "100 OVERLOOK DRIVE", "street2": "2ND FLOOR", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "604-659-5004"}, "mail-address": {"street1": "100 OVERLOOK DRIVE", "street2": "2ND FLOOR", "city": "PRINCETON", "state": "NJ", "zip": "08540"}, "former-company": [{"former-conformed-name": "ENTERPRISE TECHNOLOGIES INC", "date-changed": "20021220"}, {"former-conformed-name": "MEDCARE TECHNOLOGIES INC", "date-changed": "19960917"}]}
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April 3, 2007
Date of Report (Date of earliest event reported)
PHYTOMEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA
(State or other jurisdiction of incorporation)
000-28790
(Commission File Number)
87-0429962
(I.R.S. Employer Identification No.)
100 Overlook Drive, 2nd Floor, Princeton, NJ  08540
(Address of principal executive offices)
(800) 611-3388
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SECTION 1. Registrant's Business and Operations
Item 1.01 Entry into a Material Definitive Agreement
PhytoMedical Technologies, Inc., through its wholly owned subsidiary, PolyPhenol Technologies Corporation has entered into an expanded sponsored research agreement with Iowa State University (ISU) to develop, market and distribute novel synthesized compounds derived from type A-1 polyphenols.  This sponsored research agreement between the Iowa State University and PolyPhenol Technologies Corporation is attached as Exhibit 10.1.
SECTION 2.  Financial Information
None.
SECTION 3.  Securities and Trading Markets
None.
SECTION 4.  Matters Related to Accountants and Financial Statements
None.
SECTION 5.  Corporate Governance and Management
None.
SECTION 6. [Reserved]
N/A.
SECTION 7.  Regulation FD
None.
SECTION 8.  Other Events
None.
SECTION 9.  Financial Statements and Exhibits
Item 9.01  Financial Statements and Exhibits
The following exhibits are furnished as part of this report:
Exhibit 10.1 – Sponsored Research Agreement between PolyPhenol Technologies Corporation and Iowa State University
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PHYTOMEDICAL TECHNOLOGIES, INC.
/s/ Greg Wujek
Greg Wujek
President and CEO
Date: April 5, 2007